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Condensed Abstract
Studies using a longer time frame found a stronger association than studies using a shorter time
frame and somatic items in depression measures are positively correlated with associations of
depression with breast cancer incidence. Thus, future studies should (a) ensure sufficient periods
of time between the measurement of depression and the assessment of cancer, and (b) avoid
measuring depression using somatic items.
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Abstract
Purpose: A relationship between depression and the development of breast cancer has not been
convincingly shown in the research conducted over the past three decades.
Methods: In an effort to better understand the conflicting results, a review was conducted
focusing on the methodological problems associated with this literature, including time frame
between the assessment of depression and the diagnosis of breast cancer and the use of somatic
items in measuring depression. Fifteen breast cancer prospective studies were reviewed.
Results: While twelve of the studies found positive associations between depression and breast
cancer development, three studies found negative associations. With regards to the predictive
associations between depression and breast cancer incidence the findings revealed that (a) studies
using a longer time frame found a stronger association than studies using a shorter time frame,
and (b) studies utilizing depression measures that did not contain somatic items found a smaller
association than studies utilizing depression measures that did contain these items.
Conclusions: Future studies should ensure that sufficient periods of time between the
measurement of depression and the assessment of cancer and avoid measuring depression using
somatic items.

Keywords: depression; time frame; somatic items; development; incidence; breast cancer
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Breast cancer is consistently among the most prevalent and deadly forms of cancer.
Although death rates from breast cancer have been steadily decreasing since 1990, it ranks
second in cancer deaths among women (after lung cancer) and first in prevalence [1]. This might
be one of the reasons for the longstanding interest in the effect of psychological factors on the
development of breast cancer. Already Galen expressed the notion that psychological factors
play a role in the development of cancer [2]. The author of the first statistical report relating
cancer to psychological distress concluded that the cases in which breast cancer immediately
follows depressive emotions were too great to be caused by chance [3]. Most modern theories
proposing an influence of depression on the development of breast cancer hypothesize reduced
immune function as the connecting factor between depression and breast cancer. In other words,
depression impairs immune function, which in turn, predisposes an individual to the
development of cancer [4]. These theories are supported by studies finding reduced numbers and
functional measures of immunity in depressed individuals [5,6]. Another possible biological
mechanism connecting depression with the development of breast cancer is that depression
inhibits DNA repair mechanisms and, therefore, defense against cancer growth [7,8]. A final
way in which depression might increase the risk of breast cancer is by causing an aberrant
activity of the hypothalamic–pituitary–adrenal axis leading to a dysregulation of the stress
hormone cortisol. Cortisol is involved in the control of cell growth and regulation of the cell
cycle which explains why a flattening of cortisol levels throughout the course of a day has been
shown to increase the risk for breast cancer [9-11].
Despite the high face-validity of the aforementioned theoretical explanations for the
proposed association between depression and the development of breast cancer and more than 30
years of empirical research, including several published reviews, a clear connection, or the lack
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thereof, between the presence of depression and the development of breast cancer has not been
established [12-18]. Possible reasons for inconsistent results include insufficient consideration of
growth rates of breast cancer and inadequate assessment of depression. The purpose of this
review is to examine these possible methodological problems as they relate to the study of the
development, or initiation, of breast cancer and to estimate the associations between depression
and development of cancer after controlling for these confounding factors as far as possible.
Time Frame
Multiple reviews of empirical studies demonstrated that it takes more than 18 years for
breast cancer with an average Tumor Volume Doubling Time (TVDT) of 280 days to grow from
the first tumor cell to a tumor that is detectable [19-20]. This growth rate suggests that studies
with time frames of less than 18 years are inadequate for examining the influence of major
depression on the development of cancer; therefore, predictive associations are likely to be
underestimated.
Thus, because this review seeks to illuminate the causative role in breast cancer, this
review will focus only on studies utilizing a prospective design. Some interpret the pre-bioptic
study design, which is used in some studies focusing on breast cancer, as a variation of the
prospective design. These studies investigate people who come for diagnostic tests but do not yet
know whether or not they have cancer [21-25]. Such patients often make guesses about their
medical condition, and these expected diagnoses may influence their responses to measures of
depression [14]. These studies are limited in their ability to evaluate causality and are not able to
fully evaluate psychological variables in participants prior to the confirmation of benign,
malignant or no breast disease under similar conditions; therefore, they will not be included in
this review.
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Assessment of depression
Deciding which symptoms are part of depression and which may be attributable to cancer
is complex. There is evidence to suggest that the inclusion of somatic items may overestimate the
association between depression and cancer. For example, one study explored the role of somatic
items in the diagnosis of depression in cancer patients by dividing the Zung Self-Rating scale
into a questionnaire with and without somatic items. The questionnaire with somatic items
produced 5% more false-positive depressed cancer patients [26]. In addition, Wedding et al. [27]
analyzed the extent to which the prevalence of major depression or depressive symptoms in
cancer patients was related to somatic or affective items of the Beck Depression Inventory when
compared to healthy controls. They found that major depression and depressive symptoms were
mainly related to somatic, not affective, items and that differences compared to a healthy control
group existed mainly in the somatic items. In light of this, Endicott [28] suggested substituting
poor appetite disturbance, sleep disturbance, fatigue/loss of energy, and diminished ability to
concentrate/indecisiveness. Other authors [29], however, conclude that, while somatic symptoms
of depression are less useful than affective and cognitive symptoms, they could be used if they
were severe and proportionate to the cancer stage. In addition, cultural differences in the
expression of depression need to be considered. For example, somatic symptoms of depression
are more clearly manifest in Asian cultures than affective and cognitive symptoms [30]. Thus, it
would be important to identify the role somatic symptoms play in regards to the measured
association between depression and breast cancer. To study this problem, the following
symptoms, put forth as diagnostic criteria for a major depressive episode in the Diagnostic and
Statistical Manual of Mental Disorders (4th ed.; DSM-IV) [31] were categorized as somatic:
appetite disturbance, sleep disturbance, fatigue/loss of energy, and diminished ability to
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concentrate/ indecisiveness [28,32]. Other depression symptoms encountered in this review were
considered to be somatic if they were categorized as such by the measurement scale being used
(e.g., Zung Rating Depression Scale) [33].
Method
This review explores the evidence regarding whether major depression plays a causal role
in the development of breast cancer; therefore, we have focused only on studies utilizing a
prospective design (i.e., assess depression at one point in time, and cancer at a second, later point
in time). A literature search was conducted using Academic Search Premier, Medline,
Psychology and Behavioral Sciences Collection, and PsycINFO. Key words were depress* +
cancer, neoplasm, or tumor + longitudinal, or prospective + breast in January 2012. Secondary
searches were conducted through the references lists of relevant reviews and meta-analyses [1218]. These searches identified 481 reports; however, after removing duplicates, screening the
reports, assessing them for eligibility, and excluding all articles that did provide an indication of
the direction of the effect, 15 reports remained (see Figure 1). Time frame, assessment of
depression, analytical sample size, and incidence of breast cancer of these reports are described
in Table 1. In those reports that presented separate data for males and females, analytical sample
size and incidence of breast cancer are presented for females only.
Meta-analysis usually involves computing a weighted average effect size that represents
the magnitude of the relations of interest. This procedure presumes that the standard errors for
the effect sizes have the same conceptual meaning. Regression-based studies are challenging in
this regard, because conceptually similar variables are rarely controlled across studies. This
means that the population effects actually have different conceptual meanings across the studies,
and unless the evidence base has a very large number of studies, meta-analysis would be difficult
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due to the number of sparse or empty cells. Furthermore, prospective studies sometimes present
data in ways that make combining effect sizes across studies more difficult. For example, some
studies might carry out time-to-event analyses while others measure cross-sectional effects.
Given the conceptual differences in the meaning of effects across studies that examine
the prospective relation between depression and breast cancer, we could not rely on traditional
meta-analytic procedures. Instead, we conducted a weighted vote count of the directions of the
effect [34]. Taking into account the sample sizes from the individual studies, this procedure
exploits information about the proportion of positive to negative effects to bootstrap an estimate
of an overall weighted average effects size and its confidence interval. It is a more conservative
procedure in the sense that the resulting confidence intervals are wider than those that would
arise from a more ideal analysis (e.g., a meta-analysis of regression coefficients based on models
of exactly the same covariates across studies).
Results
Eighteen prospective studies, covering over 600,000 participants, were dedicated to
investigating the risk of breast cancer incidence associated with depression. Of these 18 studies,
three studies did not give an indication of the direction of the effect [35-37]. In other words, the
authors simply stated that the results were not statistically significant and provided no clues
regarding the sign of the effect. These three studies could not be used in the following analyses.
Of the 15 studies providing information about the direction of the effect, twelve were positive
(i.e., depression was associated with higher breast cancer incidence)1, while three were negative.
Assuming equal weights across studies (specifically, the harmonic mean sample size of 4,309),
the estimated correlation is r = +.04. Taking sample size of the individual studies into account,
It should be noted that Gross et al.’s [49] publication is an update of Gallo et al. [47] including an additional wave
of data collection which extends the time frame from 13 to 24 years. In addition, both studies use only partially
identical methodological control variables.
1
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the estimated correlation is r ≈+.025 ± .027 (95% Confidence Interval). Thus, the correlation is
not significantly different from zero.
As discussed above, these estimates are associated with uncertainty due to the potential
influence of different methodological problems (i.e., time frame between the assessment of
depression and cancer, assessment of depression). Below we present data on how the different
methodological issues were related to the effects observed in the studies. Ideally, we would have
been able to conduct a moderator analysis to determine if these observed differences in rates
were indicative of real differences in rates attributable to the study characteristics. In many
cases, however, the presence of empty cells made these analyses impossible. Consequently, we
show how different methodological choices are associated with estimated effects for some
variables; for others, we were unable to carry out this analysis.
Time Frame
The time frame necessary to study the influence of depression on breast cancer is more
than 18 years [19]. Although we recognize that the cost and time associated with conducting a
study with 18+ years of follow-up would be substantial, this length of follow-up is considered
ideal for empirical study. Of the 15 breast cancer studies in our analysis, only five had a time
frame of more than 18 years (ranging from 24 to 33 years). Six studies had a time frame
between 10 and 18 years, and four studies had a time frame of less than 10 years (Table 1).
Separating the studies based on the time frame revealed that 100% (5 of 5 studies) of the studies
with appropriate time frame (i.e., >18 years) found positive associations between depression and
breast cancer. Of the studies with shorter time frames, 70% (7 of 10 studies) found positive
associations between depression and breast cancer incidence rates.
Assessment of depression
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The studies included in this review were appraised according to their use of somatic
symptoms in assessing major depression. There was extreme variability in the methods used by
the studies to assess for depression (See Table 1), and the instruments used varied significantly in
the number and percentage of somatic items they contained (0% to 44%, Table 2). Only one of
the 15 studies reviewed utilized assessment methods that did not include any somatic items [48].
Eleven studies, on the other hand, utilized instruments that were more than 20% somatic items.
Of the studies that utilized instruments with less than 20% somatic items, 33.3% (1 of 3)
found positive and 66.6% (2 of 3) found negative associations between depression and breast
cancer. Of the studies that utilized instruments with more than 20% somatic items, 90.9% (10 of
11) found positive associations, while only 9.1% (1 of 11) study found negative associations
between depression and breast cancer. This difference suggests that somatic items may result in
an overestimation of the association between depression and breast cancer.
Discussion
The purpose of this review was to examine the effects of (a) insufficient time frame and
(b) assessment of depression including somatic items on the study of the development of breast
cancer. It was expected that an insufficiently long time frame would lead to an underestimation
of the association between depression and cancer, while the inclusion of somatic items in the
assessment of depression would lead to an overestimation of the association between depression
and breast cancer.
Using sample size as a weight, the estimated predictive associations between depression
and development of breast cancer incidence is approximately r = +.025 ± .027 (95% Confidence
Interval). Thus, the estimated predictive associations are not significant. This estimate is
associated with additional uncertainty, however, due to the possibility of the discussed
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methodological problems. Therefore, we examined how the proportion of positive (12 studies)
and negative effects (3 studies) varied as a function of studies scoring “well” vs. “not well” on
two dimensions. These findings were as predicted. Not only did a short time frame appear to
underestimate the association, but every study with an appropriate time frame found a positive
association between depression and breast cancer incidence. Furthermore, studies utilizing
measures of depression with higher percentage of somatic items were more likely to find positive
associations than studies with lower percentage of somatic items.
Clearly, the current review has limitations. All studies we identified relied on a single
diagnosis or assessment of depressive symptoms. A hypothesis linking depression and breast
cancer development presumably implies some element of chronicity; therefore, a one-time
assessment of depression with no measure of duration weakens the test of any such hypothesis
[15]. Evidence regarding the differential effects of short vs. long-term depression comes from a
study evaluating the impact of a single episode of Major Depression, recurrent episodes of Major
Depression, and Dysthymia on the development of breast cancer [41]. Single and recurrent
episodes of Major Depression did not significantly predict the development of breast cancer in
this study; however, Dysthymia did. This is interesting since an episode of Major Depression
requires more symptoms, but it can be as short as two weeks. Dysthymia, on the other hand,
requires fewer symptoms, but the symptoms need to be present for at least two years. A related
issue is the need for more thorough psychological assessment that includes different trait and
state-like constructs. Stable constructs like cognitive risk factors of depression may account for
more variance in health-related outcomes than do episodic bouts of depressive symptomatology
(i.e., episode of Major Depression). For example, rumination, a trait-like cognitive style in
which individuals respond to a sad mood by repetitively focusing their attention on their mood
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and implications of the mood, does not only prolong depressive mood [52] but is also associated
with the immune suppressive hormone cortisol, even after controlling for depressive symptoms
[53].
Regarding our methods, one drawback to the weighted vote count approach is that,
relative to a more traditional meta-analysis of effect sizes, it has lower statistical power (i.e.,
confidence intervals arising from a weighted vote count will be wider). A second potential
problem is that this procedure uses a fixed effect model, and if that model is inappropriate, the
resulting confidence intervals could be spuriously narrow. Future systematic reviews and metaanalyses would benefit from additional studies that allow for a reasonable amount of time
between the assessments of depression and cancer. Although it would be resource intensive, a
meta-analysis involving individual participant data would be a valuable contribution to this area
of research. It would allow reviewers to create conceptually similar groups of effect sizes to
better explore both the link between depression and breast cancer as well as the impact of certain
methodological choices.
Another direction for future research is to evaluate the impact of other risk factors and
regulators on the association between depression and the development of breast cancer. When
other potential risk factors and regulators are not identified, measured, and controlled for by
appropriate design or statistical techniques, they can bias the results of a study, leading
researchers to make erroneous conclusions. Thus, methodological control has a substantial
influence on the empirical findings of a study. Certain variables (e.g., smoking), however, are
likely to be stronger confounders than other variables (e.g., alcohol consumption). Thus,
systematic reviews should categorize potential confounders and then evaluate their impact on the
association between depression and development of breast cancer.
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Finally, it needs to be considered that all three studies finding negative associations
between depression and breast cancer incidence [33, 39, 43] and six studies finding positive
associations [40-42, 44, 47, 48] included fewer than 220 individuals that developed breast
cancer, while all studies finding positive associations had numbers of individuals developing
breast cancer ranging from 229 to 2,892 cases of breast cancer [38, 45, 46, 49-51]. Thus, the
small number of breast cancer cases could be another explanation for the negative associations
between depression and breast cancer incidence.
In summary, twelve studies included in the review found positive associations between
depression and breast cancer incidence while three studies found negative associations. The vote
count revealed relations between depression and breast cancer that, while not statistically
significant, were large enough to be meaningful at a population level. Perhaps even more
important is our observation that the existing literature related to depression and the development
of breast cancer revealed significant problems concerning time frame and the measures used to
assess depression. The findings related to the predictive associations between depression and
breast cancer incidences revealed that (a) studies with inappropriate short time frame
underestimate the association and (b) utilizing measures of depression with somatic items
overestimate positive associations. Although there is evidence that depression is positively
associated with breast cancer incidence, the current literature does not allow for definitive
conclusions.
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Table 1. Summary of studies examining depression and the development of breast cancer
included in the analyses
Study Author(s) & Year

Time Frame

Depression measure

(in years)

Analytical
sample/incidence of
breast cancer

Bleiker et al. [33]

13

Zung Rating Scales

9,705/217a

for Depression
Goldacre et al. [38]

33

ICD 7-10

276,627c/229a

Nykliček et al. [39]

5

EDI

5,191/58a

Gallo et al. [40]

13

DIS

1,213/25a

Gross et al. [41]

24

DIS

3,481/50a

Jacobs & Bovasso [42]

15

DIS

1,213/39a

Lichtman [43]

6

CES-D

1,458/26a

15 to 18

MMPI-1

8,932/117a

Hjerl et al. [45]

24

ICD 8

66,648/1,270a

Dalton, Mellemkjaer et al.

24

Hahn & Petitti [44]

89,491/1,391b
ICD 8

[46]
Kaplan & Reynolds [47]

17

HPL

6,848/77b

Knekt et al. [48]

14

GHQ

3,773/210a

Chen & Lin [49]

5

ICD 9

4,668/273b

Liang et al. [50]

8

ICD 9

75,771/2,892b

Schuurman et al. [51]

25

ICHPPC-2

68,366/728b
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Note: MMPI-1 = Minnesota Multiphasic Personality Inventory -1st edition, HPL = Human
Population Laboratory, CES-D = Center for Epidemiological Studies-Depression, GHQ =
General Health Questionnaire, ICD = International Classification of Diseases, DIS = Diagnostic
Interview Schedule, EDI = Edinburgh Depression Inventory, ICHPPC-2 = International
Classification of Health Problems in Primary Care, a = females only, b = females and males, c =
Goldacre et al. report an overall sample size of n = 553,254 and to calculate the analyses with
breast cancer with female participants only. However, they do not report the number females in
their sample. Thus, for the purpose of the weighted vote count, we estimated the sample would
include 50% female participants.
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Table 2. Breast cancer studies with confounding variables and direction of their findings

Study Author(s)

Time

Assessment

Effect size and

Direction of

Frame (in

(Somatic

95% CI (most

Association between

years)

Items)

adjusted model)

depression
and breast cancer

Bleiker et al. [33]

13

10 out of 20

0.75 (0.52-1.07)b

Negative

Goldacre et al. [38]

33

2 out of 6

0.92 (0.80-1.05)c

Positive

Nykliček et al. [39]

5

1 out of 10

0.29 (0.09-0.92)b

Negative

Gallo et al. [40]

13

4 out of 8

3.8 (0.5-3.4)d

Positive

Gross et al. [41]

24

4 out of 8

1.87(1.16-3.01)a

Positive

Jacobs & Bovasso

15

4 out of 8

17.2 (3.76-78.08)b

Positive

6

3 out of 20

0.9 (NR)b

Negative

15 to 18

14 out of 57

1.5 (0.9-2.5)d

Positive

Hjerl et al. [45]

24

2 out of 6

1.02 (0.97-1.08)e

Positive

Dalton,

24

2 out of 6

1.06 (0.98-1.15)e

Positive

17

4 out of 18

1.13 (NR)d

Positive

Knekt et al. [48]

14

0 out of 18

1.65 (0.60-4.58)d

Positive

Chen & Lin [49]

5

2 out of 6

1.25 (0.42-3.76)a

Positive

Liang et al. [50]

8

2 out of 6

1.09 (0.78-1.53)a

Positive

[42]
Lichtman [43]
Hahn & Petitti [44]

Mellemkjaer et al.
[46]
Kaplan &
Reynolds [47]

DEPRESSION AND BREAST CANCER

Schuurman et al.

25

1 out of 6

1.06 (0.71-1.58)a

24

Positive

[51]
Note: a = hazard ratio; b = odds ratio; c = rate ratio; d = relative risk; e = standardized incidence
ratio; (NR) = confidence interval not reported; Positive = positive association between
depression and cancer; Negative = negative association between depression and cancer.

488 records identified through
database searching

26 additional records identified
through other sources

277 records after duplicates removed

277 records screened

Eligibility

Screening

Identification

DEPRESSION AND BREAST CANCER

Included

29 full-text articles
assessed for eligibility

18 studies included in
qualitative synthesis

15 studies included in
quantitative synthesis
(meta-analysis)
Figure 1: Flowchart for the literature screening process.

Records excluded
22 not empirical
34 not longitudinal
192 not development
of cancer

Full-text articles
excluded, because
5 not breast cancer
4 psychological
factors other than
depression
2 not development of
cancer
3 articles excluded,
because they did not
provide information
on direction of
association
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